UiPath Drops 7% as Analyst Says SaaS Recovery Is Priced In
UiPath stock tumbled more than 7% overnight after Seeking Alpha downgraded the shares, arguing the SaaS recovery thesis is fully priced in at current valuations.
UiPath Drops 7% as Analyst Says SaaS Recovery Is Priced In
NEW YORK, September 4 —
UiPath, Inc. (PATH) fell more than 7% in overnight trading after a Seeking Alpha downgrade declared the SaaS recovery rally exhausted and the stock's valuation stretched.
- PATH dropped over 7% in overnight trading following the Seeking Alpha downgrade
- Shares trade at 16.7x forward earnings with 13.4% YoY revenue growth and 29.3% of float sold short, a combustible combination when sentiment turns
- Next earnings report is the proving ground: ARR growth rate guidance is the number to watch
29% Short Interest Made This Drop Hurt More Than It Should Have
The overnight move is bigger than a single analyst note deserves, and that is exactly the point. With nearly 30% of PATH's float sold short, any negative catalyst gets amplified. Shorts don't need to be right about fundamentals to push the stock around; they just need a credible headline and thin overnight liquidity. The gap-down visible in the chart is partly a valuation argument and partly a short squeeze in reverse.
The Downgrade Thesis Has One Honest Leg
Seeking Alpha's core argument, SaaS recovery is overdone, is a real debate, not a fringe take. PATH's TTM revenue sits at $1.7bn, growing 13.4% YoY, which is respectable but not the re-acceleration story needed to justify a premium multiple. FCF of $538mn is genuinely strong at 31.6% of revenue, and that is the bull's best card. But 16.7x forward earnings buys you execution risk in an automation market where enterprise budgets remain deliberate.
$0.67 EPS Versus a Multiple That Assumes Much More
The inconvenient arithmetic: PATH earns $0.67 on a trailing basis against a stock priced at $15.21. That is not a value stock. The market is paying for ARR acceleration and AI-driven upsell of UiPath's automation platform, both plausible, neither proven at the pace the current multiple demands. If next quarter's ARR growth rate guidance disappoints, the 16.7x forward P/E becomes the story's villain.
Where the Bull Case Breaks
The thesis that defeats the downgrade is simple: ARR reaccelerates above 15% and FCF continues compounding. The number that breaks it is equally specific, ARR growth guidance that prints below 12% next quarter would confirm the recovery story was multiple expansion dressed up as fundamentals. That is the line to draw before the next print arrives.
Run your own numbers on PATH with the DCF calculator, or pull the full fundamental picture at PATH's Basis Report page.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
UiPath stock dropped over 7% in overnight trading following a Seeking Alpha analyst downgrade citing the SaaS recovery as overdone.